A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
Public ClinicalTrials.gov record NCT02536339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.
Study identification
- NCT ID
- NCT02536339
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2015 (Actual)
- Primary completion
- May 1, 2019 (Actual)
- Completion
- Dec 29, 2020 (Actual)
- Last update posted
- Dec 7, 2021
2015 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Stanford Cancer Institute | Stanford | California | 94305 | — |
| University of Miami Hospital & Clinics | Miami | Florida | 33136 | — |
| H. Lee Moffitt Cancer Center and Research Inst. | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611-2987 | — |
| University of Maryland Medical Center; Department of Neurology | Baltimore | Maryland | 21201 | — |
| Associates in Oncology-Hematology, PC | Bethesda | Maryland | 20817 | — |
| Dana Farber Cancer Inst. | Boston | Massachusetts | 02115 | — |
| Allina Health System | Saint Paul | Minnesota | 55102 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| Mid Ohio Oncology Hematology;ZangMeister Center (West) | Columbus | Ohio | 43213 | — |
| Temple Cancer Center; Oncology | Philadelphia | Pennsylvania | 19140 | — |
| Methodist Hospital Research Institute | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute; University of Utah | Salt Lake City | Utah | 84112 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02536339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 7, 2021 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02536339 live on ClinicalTrials.gov.